INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure.

On September11, 2017,Insmed Incorporated (the “Company”) issued a press release announcing the closing of the public offering of 14,123,150 shares of the Company’s common stock, par value $0.01 per share, at a public offering price of $28.50 per share. A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.

Item 9.01 — Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.

Description

99.1

Press Release issued by Insmed Incorporated on September11, 2017.


INSMED Inc Exhibit
EX-99.1 2 a17-21316_3ex99d1.htm EX-99.1 Exhibit 99.1     Insmed Announces Closing of Public Offering   BRIDGEWATER,…
To view the full exhibit click here

About INSMED INCORPORATED (NASDAQ:INSM)

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.